2024-09-06 - Analysis Report
## Pfizer (PFE) Stock Analysis Report

**Company Overview:** Pfizer is a multinational pharmaceutical corporation that researches, develops, manufactures, and distributes medicines and vaccines.

**1. Performance Analysis:**

* **Cumulative Return:**  PFE has experienced a cumulative return of -26.27%, while the S&P 500 (VOO) has gained 89.66% over the same period. 
* **Relative Performance:** PFE's cumulative return is significantly lower than the S&P 500. The relative performance gap is currently -115.93, indicating that PFE's performance has been significantly worse than the S&P 500. 
* **Relative Strength:** The relative strength of PFE compared to the S&P 500 is currently at 1.28, indicating that PFE is currently outperforming the S&P 500 by 128% of its historical range.

**2. Recent Price Movements:**

* **Closing Price:** $29.01
* **5-Day Moving Average:** $28.84
* **20-Day Moving Average:** $28.85
* **60-Day Moving Average:** $28.80

**3. Technical Indicators:**

* **RSI:** 60.69, suggesting that the stock is slightly overbought, but not in a severely overbought territory.
* **PPO:** -0.02, indicating a potential weakening of the buying pressure.
* **Delta_Previous_Relative_Divergence:** -11.82, suggesting a recent short-term downward trend in relative strength.
* **Expected_Return:** 0.0%, indicating no significant expected return based on current data.

**4. Recent Earnings Performance and Outlook:**

**Recent Earnings:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

**Analysis:**

PFE's most recent earnings report for the quarter ending July 2024 showed an EPS of 0.6, exceeding the expected EPS of 0.458. This indicates a positive performance relative to analysts' expectations. Overall, PFE has been consistently exceeding earnings estimates, demonstrating a strong earnings performance.

**5. Overall Analysis:**

PFE has lagged behind the market significantly, but recently showed a positive performance in its most recent earnings report. Its technical indicators suggest a potential weakening of the buying pressure, while the RSI indicates a slightly overbought situation. PFE's future performance will be dependent on its ability to maintain a strong earnings performance and navigate the competitive pharmaceutical market effectively.

**6. Conclusion:**

While PFE's recent earnings performance is positive, its long-term performance has been significantly underperforming the broader market. Investors should carefully consider the factors mentioned above before making any investment decisions. Further analysis of its competitive landscape, regulatory environment, and future drug pipeline will be crucial in assessing the potential risks and rewards of investing in PFE. 
